Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Investigators in the laboratory of Gemma Carvill, Ph.D., assistant professor in the Ken and Ruth Davee Department of Neurology Division of Epilepsy/Clinical Neurophysiology, have discovered novel ...

ASOs, or antisense oligonucleotides, are short, synthetic sequences of single-stranded DNA that alter RNA expression or splicing in the process of translation, where genetic code (DNA) is used to ...

Dr Anup Rawool, Consultant in Clinical and Cancer Genetics at Sahyadri Hospitals, Pune, discusses innovative therapies and ...

antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S ...

An antisense drug in development at GSK has shown ... reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection in people ...

Overriding the "Off Switch" Cells function through an intricate network of proteins, each designed for specific tasks like ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis ... hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to ...

Huntington's disease is a rare genetic, autosomal dominant, neurodegenerative disease, caused by CAG repeat expansions in the HTT gene, that is polymorphic on the healthy allele and contains more than ...